Alzheimer's diagnosis advances with new blood biomarker tests

New blood biomarker tests are transforming the diagnosis of Alzheimer's disease by providing reliable data regarding pathological amyloid deposits in the brain. These advancements allow for earlier and more accurate recognition of the disease.

According to Konstantinos Lyketsos, Professor of Psychiatry at Johns Hopkins University School of Medicine, these tests are primarily intended for symptomatic patients rather than the general population for routine preventive screening. Among the available options, the p-tau217 biomarker is noted for its high reliability, as it measures a molecule originating from the brain that indicates increased amyloid pathology. Its accuracy has been compared favorably to PET scans.

In clinical practice, a highly positive p-tau217 result serves as a critical diagnostic step, particularly when considering new amyloid-targeting therapies. While a negative blood biomarker result significantly reduces the likelihood of amyloid presence, it does not entirely rule it out. In such cases, clinical presentation and further imaging, such as PET scans, remain necessary to confirm pathology and determine treatment suitability.